Nanoviricides Inc (NNVC)

$1.03 -0.02 (-1.90%)
Market Cap 24.19M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 224,600
Avg Vol 277,840
Day's Range N/A - N/A
Shares Out 21.60M
Stochastic %K 25%
Beta 1.30
Analysts Strong Sell
Price Target $6.50

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
jcooptechit
jcooptechit Mar. 20 at 7:57 PM
$NNVC EXPANDS PIPELINE AND FDA ORPHAN DRUG PLAY IN MOTION 🧬 NanoViricides recently filed for FDA Orphan Drug Designation (ODD) for NV-387 targeting measles. This could be a major strategic unlock. 📊 Why this matters: ▪️ Strong in vivo results in humanized measles model ▪️ Potential for 7 YEARS market exclusivity ▪️ Tax credits + fee exemptions = reduced costs, higher upside ▪️ Rising measles cases highlight urgent need for treatment ▪️ NV-387 advancing toward Phase II across multiple viral indications 💡 If ODD is granted, it could significantly de-risk development + enhance commercial potential. Is NNVC building a sleeper biotech story before the crowd catches on? Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 7:14 PM
$NNVC : Early Reversal Setup? 📊 NanoViricides continues advancing its antiviral platform targeting multiple virus families, while the chart is sitting near a key support zone that could determine the next move. Technical view: 1️⃣ Major support: ~$0.95–$1.05 zone 2️⃣ Price stabilizing after a prolonged downtrend, with signs of base formation 3️⃣ Recent spike in volume + failed breakdown hints at potential accumulation Reclaim levels to watch: 🔼 $1.28 first resistance area (near-term pivot) 🔼 $1.50–$1.68 next supply zone 🔼 $2.03–$2.24 key breakout range Fundamental backdrop: 🔹 Developing broad-spectrum antiviral therapies 🔹 Proprietary nanomedicine platform targeting viruses directly 🔹 Positioned in the high demand infectious disease space Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $NVAX $ADMA $VXRT $ALT
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 6:30 PM
$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
jcooptechit
jcooptechit Mar. 20 at 6:07 PM
$NNVC ACCUMULATION PHASE NEARLY COMPLETE? WATCH THESE LEVELS NanoViricides is holding strong in the .95–1.05 accumulation zone as bulls continue to step in ahead of pipeline catalysts. 🧬 📊 Key Levels: ▪️ Support: .95–1.05 (major base) ▪️ Pivot: 1.25 ▪️ Momentum Trigger: 1.49 ▪️ Resistance: 1.66 - 1.86 - 2.00 - 2.25 (Nov ‘25 high) A reclaim of 1.25 - 1.49 with volume could bring momentum traders back fast and open the door to $2.00+. With clinical progress advancing and attention building, this looks like accumulation before the next move. 🔥 Watch closely: this could move quick once it breaks. Do your DD. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 3:21 PM
$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly. Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug. Recent milestones 🔸Completed Phase 1 safety trials 🔸Advanced manufacturing for Phase 2-ready drug 🔸Preparing for Phase 2 (Mpox focus) Catalysts 🔸Phase 2 launch + data 🔸Expansion into additional viral targets 🔸Regulatory updates / partnerships The antiviral market is already ~$60–70B, with long-term growth toward ~$90B+ NNVC is a microcap trying to capture that with a multi-virus approach Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
jcooptechit
jcooptechit Mar. 20 at 2:55 PM
PHASE II READY $NNVC CHECKED MULTIPLE MAJOR BOXES 🔬 NanoViricides is stepping into a critical inflection point and the market may not be pricing it in yet What You Should Know: ✔️ Phase II clinical product NV-387 Oral Gummies FULLY MANUFACTURED ✔️ Phase I completed with NO adverse events ✔️ Regulatory clearance secured to enter Phase II for Monkeypox (MPox) ✔️ Presenting at NIBA’s 152nd Investment Conference—prime investor exposure Execution + clinical progression + visibility all aligning. With safety already demonstrated and Phase II cleared, NV-387 could be a serious player in antiviral treatment, especially with global MPox concerns still on the radar. 💡 The question: Is Wall Street asleep on NNVC before Phase II momentum kicks in? Do your DD and stay ahead. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
Rampart1
Rampart1 Mar. 20 at 2:11 PM
NanoViricides **( NYSE: $NNVC )** NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial Technical Analysis: Buyers present on the trendline Volume gap ahead Over sold RSI It appears that NNVC gave up its gains from the recent news driven run from .96 to 1.27. Now I am watching this due to the fundamental and technical setup. Communicated Disclaimer https://tinyurl.com/DoctorDDDisclaimer
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Mar. 20 at 1:22 PM
NanoViricides ( NYSE: $NNVC ) NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial Technical Analysis: - Buyers present on the trendline - Volume gap ahead - Over sold RSI It appears that NNVC gave up its gains from the recent news driven run from .96 to 1.27. Now I am watching this due to the fundamental and technical setup. Communicated Disclaimer https://www.ztradez.net/communicated-disclaimer $OPEN $ONDS
1 · Reply
Love1010
Love1010 Mar. 19 at 7:54 PM
$NNVC @STRAYNUT 20 years later and this guy is still blaming a so called short cabal. Comical!
0 · Reply
Love1010
Love1010 Mar. 18 at 12:47 PM
$NNVC it is designed for failure
0 · Reply
Latest News on NNVC
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

Mar 11, 2026, 8:30 AM EDT - 10 days ago

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 12, 2026, 8:30 AM EST - 5 weeks ago

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 10, 2026, 8:30 AM EST - 5 weeks ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

Feb 2, 2026, 8:30 AM EST - 6 weeks ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

Jan 13, 2026, 8:30 AM EST - 2 months ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Dec 1, 2025, 8:30 AM EST - 3 months ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Nov 17, 2025, 8:30 AM EST - 4 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 14, 2025, 8:30 AM EST - 4 months ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 12, 2025, 5:01 PM EST - 4 months ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 4 months ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 10, 2025, 8:30 AM EST - 4 months ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 5, 2025, 8:30 AM EST - 4 months ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Nov 3, 2025, 8:30 AM EST - 4 months ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 29, 2025, 8:45 AM EDT - 5 months ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 27, 2025, 8:45 AM EDT - 5 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 22, 2025, 8:45 AM EDT - 5 months ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 20, 2025, 8:45 AM EDT - 5 months ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Oct 15, 2025, 8:45 AM EDT - 5 months ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 6 months ago

NanoViricides, Inc. Has Filed its Annual Report

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 11, 2025, 8:30 AM EDT - 6 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 6 months ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Aug 18, 2025, 8:30 AM EDT - 7 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 30, 2025, 8:30 AM EDT - 8 months ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 23, 2025, 8:30 AM EDT - 8 months ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025, 6:30 AM EDT - 8 months ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 8 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 18, 2025, 6:30 AM EDT - 9 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 10 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025, 6:30 AM EDT - 10 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 22, 2025, 6:30 AM EDT - 10 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 14, 2025, 6:30 AM EDT - 11 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025, 6:30 AM EDT - 11 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 29, 2025, 6:30 AM EDT - 11 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Apr 14, 2025, 6:30 AM EDT - 1 year ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 11, 2025, 6:30 AM EDT - 1 year ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Mar 4, 2025, 6:30 AM EST - 1 year ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed its Quarterly Report

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Feb 11, 2025, 6:30 AM EST - 1 year ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 29, 2025, 6:30 AM EST - 1 year ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 27, 2025, 6:30 AM EST - 1 year ago

NanoViricides Engages CRO for Phase II Clinical Trial

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 13, 2025, 6:30 AM EST - 1 year ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Jan 8, 2025, 6:30 AM EST - 1 year ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Dec 23, 2024, 6:30 AM EST - 1 year ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Nov 4, 2024, 12:00 AM EST - 1 year ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 22, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Oct 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Sep 26, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

jcooptechit
jcooptechit Mar. 20 at 7:57 PM
$NNVC EXPANDS PIPELINE AND FDA ORPHAN DRUG PLAY IN MOTION 🧬 NanoViricides recently filed for FDA Orphan Drug Designation (ODD) for NV-387 targeting measles. This could be a major strategic unlock. 📊 Why this matters: ▪️ Strong in vivo results in humanized measles model ▪️ Potential for 7 YEARS market exclusivity ▪️ Tax credits + fee exemptions = reduced costs, higher upside ▪️ Rising measles cases highlight urgent need for treatment ▪️ NV-387 advancing toward Phase II across multiple viral indications 💡 If ODD is granted, it could significantly de-risk development + enhance commercial potential. Is NNVC building a sleeper biotech story before the crowd catches on? Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 7:14 PM
$NNVC : Early Reversal Setup? 📊 NanoViricides continues advancing its antiviral platform targeting multiple virus families, while the chart is sitting near a key support zone that could determine the next move. Technical view: 1️⃣ Major support: ~$0.95–$1.05 zone 2️⃣ Price stabilizing after a prolonged downtrend, with signs of base formation 3️⃣ Recent spike in volume + failed breakdown hints at potential accumulation Reclaim levels to watch: 🔼 $1.28 first resistance area (near-term pivot) 🔼 $1.50–$1.68 next supply zone 🔼 $2.03–$2.24 key breakout range Fundamental backdrop: 🔹 Developing broad-spectrum antiviral therapies 🔹 Proprietary nanomedicine platform targeting viruses directly 🔹 Positioned in the high demand infectious disease space Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $NVAX $ADMA $VXRT $ALT
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 6:30 PM
$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
jcooptechit
jcooptechit Mar. 20 at 6:07 PM
$NNVC ACCUMULATION PHASE NEARLY COMPLETE? WATCH THESE LEVELS NanoViricides is holding strong in the .95–1.05 accumulation zone as bulls continue to step in ahead of pipeline catalysts. 🧬 📊 Key Levels: ▪️ Support: .95–1.05 (major base) ▪️ Pivot: 1.25 ▪️ Momentum Trigger: 1.49 ▪️ Resistance: 1.66 - 1.86 - 2.00 - 2.25 (Nov ‘25 high) A reclaim of 1.25 - 1.49 with volume could bring momentum traders back fast and open the door to $2.00+. With clinical progress advancing and attention building, this looks like accumulation before the next move. 🔥 Watch closely: this could move quick once it breaks. Do your DD. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 3:21 PM
$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly. Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug. Recent milestones 🔸Completed Phase 1 safety trials 🔸Advanced manufacturing for Phase 2-ready drug 🔸Preparing for Phase 2 (Mpox focus) Catalysts 🔸Phase 2 launch + data 🔸Expansion into additional viral targets 🔸Regulatory updates / partnerships The antiviral market is already ~$60–70B, with long-term growth toward ~$90B+ NNVC is a microcap trying to capture that with a multi-virus approach Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
jcooptechit
jcooptechit Mar. 20 at 2:55 PM
PHASE II READY $NNVC CHECKED MULTIPLE MAJOR BOXES 🔬 NanoViricides is stepping into a critical inflection point and the market may not be pricing it in yet What You Should Know: ✔️ Phase II clinical product NV-387 Oral Gummies FULLY MANUFACTURED ✔️ Phase I completed with NO adverse events ✔️ Regulatory clearance secured to enter Phase II for Monkeypox (MPox) ✔️ Presenting at NIBA’s 152nd Investment Conference—prime investor exposure Execution + clinical progression + visibility all aligning. With safety already demonstrated and Phase II cleared, NV-387 could be a serious player in antiviral treatment, especially with global MPox concerns still on the radar. 💡 The question: Is Wall Street asleep on NNVC before Phase II momentum kicks in? Do your DD and stay ahead. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
Rampart1
Rampart1 Mar. 20 at 2:11 PM
NanoViricides **( NYSE: $NNVC )** NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial Technical Analysis: Buyers present on the trendline Volume gap ahead Over sold RSI It appears that NNVC gave up its gains from the recent news driven run from .96 to 1.27. Now I am watching this due to the fundamental and technical setup. Communicated Disclaimer https://tinyurl.com/DoctorDDDisclaimer
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Mar. 20 at 1:22 PM
NanoViricides ( NYSE: $NNVC ) NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial Technical Analysis: - Buyers present on the trendline - Volume gap ahead - Over sold RSI It appears that NNVC gave up its gains from the recent news driven run from .96 to 1.27. Now I am watching this due to the fundamental and technical setup. Communicated Disclaimer https://www.ztradez.net/communicated-disclaimer $OPEN $ONDS
1 · Reply
Love1010
Love1010 Mar. 19 at 7:54 PM
$NNVC @STRAYNUT 20 years later and this guy is still blaming a so called short cabal. Comical!
0 · Reply
Love1010
Love1010 Mar. 18 at 12:47 PM
$NNVC it is designed for failure
0 · Reply
Mobler12
Mobler12 Mar. 16 at 8:49 PM
$NNVC MPOX in NYC , measles continues to spread https://www.foxnews.com/health/first-case-severe-mpox-disease-reported-major-city-life-threatening
1 · Reply
Mobler12
Mobler12 Mar. 16 at 8:47 PM
$NNVC
0 · Reply
STRAYNUT
STRAYNUT Mar. 15 at 1:34 PM
$NNVC As of March 12, 2026, the "Short Cabal" was "naked" short almost 1 million shares, about 5% of the float. Assuming today's volume was inflated by half, we believe practically the entire volume was shorted, as the volume lately has averaged only 50,000-100,000 shares per day and that may have been largely shorted. THERE IS NO LEGITIMATE STOCK FOR SALE and the "street" is slowly waking up to that fact. IMO
0 · Reply
STRAYNUT
STRAYNUT Mar. 15 at 1:32 PM
$NNVC NanoViricides Revolutionary Platform Technology For Treatment of Antiviral Infections: One Lead Drug Alone Addresses a $2.5 to $4.3 Billion Market https://www.nanoviricides.com/files/News%20PDFs/2024-09-18%20NanoViricides%20Presentation%20-%20with%20Markets.pdf
0 · Reply
STRAYNUT
STRAYNUT Mar. 15 at 1:30 PM
$NNVC A Revolutionary Strategy for Viral Infections Emperic Treatment with NV-387 is Possible Stock Symbol: NNVC (NYSE AmericanJust Like Emperic Treatment of Bacterial Infections Became Possible with Penicillin) Presentation at the BIO International Convention 2025 June 16, 2025 https://www.nanoviricides.com/files/News%20PDFs/Broad-Spectrum%20NV-387%20To%20Enable%20Emperic%20Antiviral%20Treatment%20-%20A%20Revolutionary%20Prospect%20Reminisc.pdf
0 · Reply
Love1010
Love1010 Mar. 13 at 1:56 PM
$NNVC new bagholders unite!
0 · Reply
Love1010
Love1010 Mar. 13 at 1:20 PM
$NNVC not reliable not authentic not copesetic
0 · Reply
StockScanners
StockScanners Mar. 13 at 4:28 AM
$NNVC reached 1.27
0 · Reply
Love1010
Love1010 Mar. 12 at 4:57 PM
$NNVC don't get excited... Diwan will never test the Cides on humans. Mark it.
1 · Reply
Knucklehead_
Knucklehead_ Mar. 12 at 3:15 PM
$NNVC Typical bear bull struggle, bears try to control in the morning, bulls run in the afternoon. If bulls can get control, there’s little holding it back from an epic ATH. Cheers 🥂
0 · Reply
drkazmd65
drkazmd65 Mar. 12 at 2:39 PM
$NNVC - A lot of trading activity here today, and so far in a positive directly for share prices. Will the viruscide work against Monkey Pox? Who knows at this stage. The compound has been very effective in animal models, but will it significantly improve outcomes for an actual human disease?
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 12 at 2:15 PM
$NNVC $HOTH the market is bad but the Pitt is green and not done yet..... 🥑🥑🥑🥑
0 · Reply